Open AccessP704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
Author(s) -
Hughes T.,
Cortes J. E.,
Réa D.,
Mauro M. J.,
Hochhaus A.,
Kim D.W.,
Sasaki K.,
Lang F.,
Heinrich M. C.,
Breccia M.,
Deininger M.,
Goh Y.T.,
Janssen J. J.,
Talpaz M.,
Gómez García de Soria V.,
Coutre P.,
Kapoor S.,
Cacciatore S.,
Polydoros F.,
Agrawal N.,
Mahon F.X.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845700.84142.c0
Subject(s) - medicine , discontinuation , ponatinib , bosutinib , clinical trial , myeloid leukemia , oncology , nilotinib , imatinib